Paroxysmal nocturnal hemoglobinuria secondary prevention: Difference between revisions

	Paroxysmal nocturnal hemoglobinuria Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Paroxysmal nocturnal hemoglobinuria from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Paroxysmal nocturnal hemoglobinuria secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Paroxysmal nocturnal hemoglobinuria secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Paroxysmal nocturnal hemoglobinuria secondary prevention
CDC on Paroxysmal nocturnal hemoglobinuria secondary prevention
Paroxysmal nocturnal hemoglobinuria secondary prevention in the news
Blogs on Paroxysmal nocturnal hemoglobinuria secondary prevention
Directions to Hospitals Treating Paroxysmal nocturnal hemoglobinuria
Risk calculators and risk factors for Paroxysmal nocturnal hemoglobinuria secondary prevention

Revision as of 17:02, 2 July 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include:

@@ Line 1: / Line 1: @@
 __NOTOC__
-{{ Paroxysmal nocturnal hemoglobinuria }}
+{{Paroxysmal nocturnal hemoglobinuria}}
-{{CMG}}
+{{CMG}}; {{AE}}
-Please help WikiDoc by adding content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
 ==Overview==
+There are no established measures for the secondary prevention of [disease name].
+OR
+Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
 ==Secondary Prevention==
+There are no established measures for the secondary prevention of [disease name].
+OR
+Effective measures for the secondary prevention of [disease name] include:
+*[Strategy 1]
+*[Strategy 2]
+*[Strategy 3]
 ==References==
 {{Reflist|2}}
-[[Category:Hematology]]
-[[Category:Rheumatology]]
-[[Category:Mature chapter]]
 {{WH}}
 {{WS}}
+[[Category: (name of the system)]]